Raquel Fabreti-Oliveira

Dr. Raquel Fabreti-Oliveira

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2018 in Immunogenetics
Verified
Journal Article
Closed access
PDF file
MHMichael Halagan
Michael Halagan
DODanielli Cristina Oliveira
Danielli Cristina Oliveira
MMMartin Maiers
Martin Maiers
RFRaquel Fabreti-Oliveira
Raquel Fabreti-Oliveira
MMMaria Elisa Hue Moraes
Maria Elisa Hue Moraes
LPLuis Cristóvão Porto
Luis Cristóvão Porto

13 August 2019 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
MLMarcus Faria Lasmar
Marcus Faria Lasmar
RDRodrigo Santana Dutra
Rodrigo Santana Dutra
JNJosé Augusto Nogueira-Machado
José Augusto Nogueira-Machado
RFRaquel Fabreti-Oliveira
Raquel Fabreti-Oliveira
RSRaquel Gomes Siqueira
Raquel Gomes Siqueira
ENEvaldo Nascimento
Evaldo Nascimento
In kidney transplantation, immunotherapy with thymoglobulin (rATG) has been used to down-regulate the patient immune system. rATG is a powerful immunobiologic drug used to deplete lymphocytes to prevent early acute rejection. The aim of this research was to evaluate the effects of immunotherapy by rATG on graft suvival during a 9-year period in kidney-transplanted patients with different immunological profiles. A sample of 469 patients were allocated into four groups (G) based on immunological risk of rejection: G1, low risk, not sensitized recipients, solid-phase immunoassay with single antigen beads (SPI-SAB) < 10%; G2, medium risk I, sensitized recipients, SPI-SAB ≥ 10 < 50%; G3, medium risk II sensitized (SPI-SAB ≥50%); and G4, high risk, sensitized recipients, SPI-SAB- donor-specific antibody positive (DSA+). Only patients from G3 and G4 received immunotherapy. Of 255 patients who received a kidney from a living donor (LD), 42 (16.47%) from all groups (G) had T-cell–mediated rejection (TCMR) and four (G1) lost their grafts, 8 (3.14%) had antibody-mediated rejection (AMR), and two lost their graft in G1 and G4. Of 214 patients who received a kidney from deceased donors (DD), 37 (17.29%) had TCMR with one lost graft in G1. AMR was shown in 13 (6.07%) patients, with three losses observed in G2. Statistical differences between the groups in the 9-year graft survival rate were found only in the comparison of G1 versus G2 (P = 0.005) and G2 versus G4 (P = 0.047) for DD. For LD, no statistical differences were found. This clinical retrospective study shows that immunotherapy induction was associated with improvement of outcomes, graft function, and survival in patients treated with immunotherapy in comparison with patients who did not received induction therapy. These findings strongly suggest that immunotherapy should be used for all patients transplanted with kidneys from deceased donors.

12 April 2014 in Tissue Antigens
Verified
Journal Article
Closed access
PDF file
RFRaquel Fabreti-Oliveira
Raquel Fabreti-Oliveira
RAR. A.
R. A.
ENE. Nascimento
E. Nascimento
CFC. G. Fonseca
C. G. Fonseca
MSM. A. Santos
M. A. Santos

17 September 2018 in HLA
Verified
Journal Article
Closed access
PDF file
PRPâmela G. Reis
Pâmela G. Reis
EAEliane P. Ambrosio‐Albuquerque
Eliane P. Ambrosio‐Albuquerque
RFRaquel Fabreti-Oliveira
Raquel Fabreti-Oliveira
RMRicardo A. Moliterno
Ricardo A. Moliterno
VSVictor Souza
Victor Souza
Jeane Eliete Laguila VisentainerJeane Eliete Laguila Visentainer
Jeane Eliete Laguila Visentainer

1 July 2022 in Transplantation Proceedings
Verified
Journal Article
Closed access
ENEdson Henrique Gabriel Nascimento
Edson Henrique Gabriel Nascimento
ENEvaldo Nascimento
Evaldo Nascimento
MLMarcus F. Lasmar
Marcus F. Lasmar
RFRaquel Fabreti-Oliveira
Raquel Fabreti-Oliveira

11 February 2025 in HLA
Verified
Journal Article
Closed access
JSJose Samuel da Silva
Jose Samuel da Silva
Jeane Eliete Laguila VisentainerJeane Eliete Laguila Visentainer
Jeane Eliete Laguila Visentainer
RFRaquel Fabreti-Oliveira
Raquel Fabreti-Oliveira
FSFelipe Carlos Brito de Souza
Felipe Carlos Brito de Souza
MSMarcio Nogueira Pereira Silva
Marcio Nogueira Pereira Silva
LPLuis Cristóvão Porto
Luis Cristóvão Porto